$VANI

Williams Gregg purchased $2.0M of VANI (indirect holdings)

Williams Gregg purchased 1,587,301 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($2.00M total) on 2026-06-15.

Original reporting
SEC EDGAR · Williams Gregg
Published Jun 16, 2026, 1:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VANI
Bullish
medium confidence
Mentioned
$VANI
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VANIBullishLow
01

Why it matters

The newest concrete fact is the disclosed open-market purchase size, price, and post-transaction holdings; it may marginally influence sentiment but does not change company fundamentals in the text.

02

Market read

Traders may view the filing as a small bullish signal, but it is unlikely to drive a sustained repricing without accompanying operational news.

03

What to watch

The purchase is indirect and the article provides no context on prior holdings, motivation, or whether other insiders/large holders are acting similarly.

Relevance 7/10Novelty 6/10Timing: Filed 2026-06-16; purchase dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Vivani Medical, Inc.

Company-level read

Ticker impact

$VANIBullishMedium confidence
Context

SEC Form 4 shows Vivani Medical director/10% owner Williams Gregg bought 1,587,301 shares of VANI on 2026-06-15.

Expected impact

Likely minimal near-term price impact; may slightly support sentiment if market treats it as bullish.

Evidence & confidence

The filing is primary-source and specific, but Form 4 insider buys are often routine and not a new operating catalyst.

Market effects

No sector-wide read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

A director/10% owner buy can be driven by diversification, liquidity needs, or pre-planned trading rather than a new bullish thesis (notably, no 10b5-1 plan is cited).

Key entities

  • Vivani Medical, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Williams Gregg

    Director and 10% owner who reported an indirect open-market purchase of VANI shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VANIMed

Vivani Medical, Inc. (VANI): Results of Operations and Financial Condition

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight mana

$VANIMed

Vivani Flat on Hookup with Novo

Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. Vivani noted no exclusivity. It plans to start a Phase 1 first-in-human study mid-2026, using Wegovy as comparator, to support a Phase 2 dose-ranging study.

$VANIMedAI 8/10

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO), with Cortigent becoming a wholly owned ClearOne unit. ClearOne plans a concurrent $10–15M financing via an S-1. Vivani will receive 12.5M ClearOne shares for 59.4%–67.5% ownership; ClearOne will rename to Cortigent Holdings (CRGT), expected to close Q3 2026.

$VANIMedAI 8/10

Vivani Medical, Inc.: Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO) via a definitive agreement, making Cortigent a wholly owned ClearOne unit. ClearOne plans a concurrent $10m–$15m financing. Vivani will receive 12.5m ClearOne shares and own 59.4%–67.5%; the combined company will trade as CRGT, expected to close Q3 2026.